METADATE ER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for METADATE ER (METADATE ER).
Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.
| Metabolism | Primarily hepatic via carboxylesterase CES1A1 to inactive metabolite ritalinic acid. Minor pathways include oxidative metabolism via CYP2D6. The drug undergoes extensive first-pass metabolism. |
| Excretion | Renal (80% as metabolites, <1% unchanged); fecal (10-20%) via biliary elimination. |
| Half-life | Terminal elimination half-life: 3-6 hours (mean 4.5 hours) for methylphenidate; clinical context: requires multiple daily dosing or extended-release formulation. |
| Protein binding | 10-33% (primarily albumin). |
| Volume of Distribution | Vd: 2-4 L/kg; indicates extensive tissue distribution and penetration into the central nervous system. |
| Bioavailability | Oral: 30% (due to first-pass metabolism); Metadate ER: similar to immediate-release with extended dissolution profile. |
| Onset of Action | Oral immediate-release: 30-60 minutes; extended-release (Metadate ER): 1-2 hours. |
| Duration of Action | Metadate ER: approximately 8 hours (due to biphasic release); clinical note: effects may vary with individual metabolism. |
| Molecular Weight | 373.9 |
Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (eGFR <30 mL/min/1.73m²) and consider dose reduction based on tolerability. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Not recommended. |
| Pediatric use | Age ≥6 years: Initial 10-20 mg orally once daily; increase by 10 mg weekly. Maximum: 60 mg/day or 2 mg/kg/day, whichever is less. |
| Geriatric use | Initiate at lower doses (e.g., 10 mg once daily) with cautious titration due to increased sensitivity and higher risk of adverse effects such as hypertension, agitation, and insomnia. |
| 1st trimester | Limited human data; animal studies show increased risk of malformations. Use only if benefit outweighs risk. |
| 2nd trimester | May cause fetal tachycardia and growth restriction; monitor fetal growth. |
| 3rd trimester | Risk of neonatal withdrawal symptoms (irritability, tremors) and low birth weight. Avoid in late pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for METADATE ER (METADATE ER).
| Placental transfer | Crosses placenta; detected in fetal plasma. |
| Breastfeeding | Drug excreted in breast milk in low amounts; potential for infant agitation and sleep disturbances. Consider benefits vs risks. |
| Lactation Rating |
■ FDA Black Box Warning
METADATE ER has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events. Physicians should assess the risk of abuse before prescribing and monitor for signs of abuse during therapy.
| Serious Effects |
Hypersensitivity to methylphenidateMarked anxiety, tension, agitationGlaucomaTics or Tourette's syndromeConcurrent MAOI use or within 14 days
| Precautions | Serious cardiovascular events including sudden death in patients with structural cardiac abnormalities or other serious heart problems, Increased blood pressure and heart rate, Psychiatric adverse reactions including exacerbation of pre-existing psychosis, mania, or aggression, Seizures in patients with history of seizure disorders, Long-term suppression of growth in children, Potential for peripheral vasculopathy including Raynaud's phenomenon, Serotonin syndrome when used with serotonergic drugs, Hematologic effects such as leukopenia and thrombocytopenia |
| Food/Dietary | Take with or without food. High-fat meals may delay the rate of absorption but not the extent. Avoid excessive caffeine intake as it may increase side effects like nervousness and palpitations. Alcohol should be avoided due to risk of altered release and increased adverse effects. |
Loading safety data…
| L3 - Moderately Safe |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (including irritability, dysphoria, and feeding difficulties). |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate regularly; assess for symptoms of preeclampsia. Fetal ultrasound to monitor growth and amniotic fluid volume. Neonatal monitoring for withdrawal symptoms and appropriate weight gain after delivery. |
| Fertility Effects | No known adverse effects on fertility in animal studies; limited human data. May improve fertility in women with ADHD by enhancing treatment adherence and reducing impulsive behaviors. |
| Clinical Pearls | METADATE ER is an extended-release formulation of methylphenidate. Avoid crushing or chewing capsules to prevent rapid release and potential toxicity. Monitor for blood pressure and heart rate changes, especially in patients with pre-existing cardiovascular conditions. Use with caution in patients with a history of seizures or drug dependence. Discontinue if signs of psychosis or severe depression occur. |
| Patient Advice | Take exactly as prescribed; do not crush or chew capsules. · Swallow whole with or without food, usually in the morning. · Report any chest pain, shortness of breath, or fainting immediately. · Avoid alcohol while taking this medication. · Store at room temperature away from moisture and heat. · Do not suddenly stop taking without consulting your doctor. · May impair ability to drive or operate machinery until effects are known. |